Eli Lilly’s current evaluation agreement with Peptron grants only a non-exclusive R&D license for feasibility testing of the SmartDepot sustained-release PLGA microsphere platform on select peptides, with any commercial rights left optional and uncommitted. The original 14-month term was extended to a maximum of 24 months ending around October 2026, yet no technology-transfer or commercialization deal has emerged after roughly 20 months of joint work. Mid-2026 reporting shows Lilly continuing internal validation while actively pursuing alternative long-acting delivery technologies such as Camurus, leaving little runway for a binding licensing agreement before the deadline. Trader consensus reflected in the 87.5% implied probability for No therefore rests on the absence of momentum toward a full commercial commitment and the structural limits of the existing evaluation framework.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วEli Lilly licenses Peptron’s SmartDepot by October 7?
Eli Lilly licenses Peptron’s SmartDepot by October 7?
$11,138 ปริมาณ
$11,138 ปริมาณ
Oct 7, 2026
$11,138 ปริมาณ
$11,138 ปริมาณ
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s current evaluation agreement with Peptron grants only a non-exclusive R&D license for feasibility testing of the SmartDepot sustained-release PLGA microsphere platform on select peptides, with any commercial rights left optional and uncommitted. The original 14-month term was extended to a maximum of 24 months ending around October 2026, yet no technology-transfer or commercialization deal has emerged after roughly 20 months of joint work. Mid-2026 reporting shows Lilly continuing internal validation while actively pursuing alternative long-acting delivery technologies such as Camurus, leaving little runway for a binding licensing agreement before the deadline. Trader consensus reflected in the 87.5% implied probability for No therefore rests on the absence of momentum toward a full commercial commitment and the structural limits of the existing evaluation framework.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 5, 2026, 8:02 PM ET
ปริมาณการซื้อขาย
$11,138วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s current evaluation agreement with Peptron grants only a non-exclusive R&D license for feasibility testing of the SmartDepot sustained-release PLGA microsphere platform on select peptides, with any commercial rights left optional and uncommitted. The original 14-month term was extended to a maximum of 24 months ending around October 2026, yet no technology-transfer or commercialization deal has emerged after roughly 20 months of joint work. Mid-2026 reporting shows Lilly continuing internal validation while actively pursuing alternative long-acting delivery technologies such as Camurus, leaving little runway for a binding licensing agreement before the deadline. Trader consensus reflected in the 87.5% implied probability for No therefore rests on the absence of momentum toward a full commercial commitment and the structural limits of the existing evaluation framework.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$11,138วันสิ้นสุด
Oct 7, 2026ตลาดเปิดเมื่อ
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s current evaluation agreement with Peptron grants only a non-exclusive R&D license for feasibility testing of the SmartDepot sustained-release PLGA microsphere platform on select peptides, with any commercial rights left optional and uncommitted. The original 14-month term was extended to a maximum of 24 months ending around October 2026, yet no technology-transfer or commercialization deal has emerged after roughly 20 months of joint work. Mid-2026 reporting shows Lilly continuing internal validation while actively pursuing alternative long-acting delivery technologies such as Camurus, leaving little runway for a binding licensing agreement before the deadline. Trader consensus reflected in the 87.5% implied probability for No therefore rests on the absence of momentum toward a full commercial commitment and the structural limits of the existing evaluation framework.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย